BioNTech Valuation
Is 22UA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 22UA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 22UA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 22UA's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 22UA?
Key metric: As 22UA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 22UA's PS Ratio? | |
|---|---|
| PS Ratio | 9x |
| Sales | €3.04b |
| Market Cap | €27.42b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.3x |
| Enterprise Value/EBITDA | -36.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 22UA's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.3x | ||
BIO3 Biotest | 1.5x | 3.6% | €1.3b |
FYB Formycon | 14.5x | 33.4% | €882.8m |
BAYN Bayer | 0.4x | 1.0% | €19.0b |
SRT3 Sartorius | 4.6x | 9.3% | €13.9b |
22UA BioNTech | 9x | 3.4% | €28.9b |
Price-To-Sales vs Peers: 22UA is expensive based on its Price-To-Sales Ratio (9x) compared to the peer average (5.3x).
Price to Sales Ratio vs Industry
How does 22UA's PS Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Sales vs Industry: 22UA is expensive based on its Price-To-Sales Ratio (9x) compared to the European Biotechs industry average (8x).
Price to Sales Ratio vs Fair Ratio
What is 22UA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 9x |
| Fair PS Ratio | 5.1x |
Price-To-Sales vs Fair Ratio: 22UA is expensive based on its Price-To-Sales Ratio (9x) compared to the estimated Fair Price-To-Sales Ratio (5.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €113.50 | €129.50 +14.1% | 9.6% | €163.73 | €115.42 | n/a | 18 |
| Nov ’25 | €102.40 | €119.08 +16.3% | 17.1% | €157.49 | €82.32 | n/a | 18 |
| Oct ’25 | €106.90 | €111.46 +4.3% | 19.6% | €153.73 | €76.42 | n/a | 18 |
| Sep ’25 | €79.20 | €99.20 +25.3% | 20.4% | €155.58 | €77.33 | n/a | 18 |
| Aug ’25 | €75.55 | €103.43 +36.9% | 20.3% | €158.55 | €83.53 | n/a | 18 |
| Jul ’25 | €74.35 | €103.54 +39.3% | 20.2% | €159.58 | €83.53 | n/a | 18 |
| Jun ’25 | €92.25 | €103.10 +11.8% | 20.4% | €158.71 | €83.26 | n/a | 18 |
| May ’25 | €83.65 | €106.61 +27.5% | 20.7% | €157.51 | €83.26 | n/a | 18 |
| Apr ’25 | €86.10 | €108.69 +26.2% | 23.6% | €173.24 | €83.26 | n/a | 18 |
| Mar ’25 | €85.08 | €116.57 +37.0% | 22.5% | €173.24 | €91.15 | n/a | 17 |
| Feb ’25 | €85.96 | €117.42 +36.6% | 22.4% | €173.24 | €91.15 | n/a | 16 |
| Jan ’25 | €95.02 | €120.35 +26.7% | 21.0% | €168.70 | €91.15 | n/a | 16 |
| Dec ’24 | €90.20 | €123.84 +37.3% | 23.0% | €182.92 | €91.15 | n/a | 17 |
| Nov ’24 | €88.32 | €131.90 +49.3% | 23.1% | €182.92 | €96.35 | €102.40 | 17 |
| Oct ’24 | €99.88 | €138.26 +38.4% | 22.9% | €186.14 | €93.84 | €106.90 | 16 |
| Sep ’24 | €113.15 | €142.84 +26.2% | 26.1% | €228.18 | €90.88 | €79.20 | 17 |
| Aug ’24 | €97.80 | €147.17 +50.5% | 24.7% | €228.18 | €98.93 | €75.55 | 17 |
| Jul ’24 | €99.00 | €151.88 +53.4% | 23.1% | €228.18 | €98.93 | €74.35 | 16 |
| Jun ’24 | €97.46 | €149.76 +53.7% | 23.4% | €228.18 | €98.93 | €92.25 | 17 |
| May ’24 | €102.05 | €162.50 +59.2% | 23.7% | €240.01 | €116.67 | €83.65 | 17 |
| Apr ’24 | €113.60 | €169.58 +49.3% | 22.2% | €240.01 | €120.58 | €86.10 | 16 |
| Mar ’24 | €119.60 | €193.08 +61.4% | 23.4% | €278.56 | €132.36 | €85.08 | 15 |
| Feb ’24 | €129.20 | €192.94 +49.3% | 23.5% | €278.56 | €132.81 | €85.96 | 15 |
| Jan ’24 | €143.00 | €201.23 +40.7% | 23.2% | €309.57 | €143.71 | €95.02 | 15 |
| Dec ’23 | €160.50 | €204.32 +27.3% | 22.4% | €309.57 | €144.45 | €90.20 | 16 |
| Nov ’23 | €143.40 | €212.20 +48.0% | 24.6% | €318.12 | €133.57 | €88.32 | 16 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Teva Pharmaceutical Industries
US$18.8b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEV
US$15.55
7D
-4.0%
1Y
78.7%
Collegium Pharmaceutical
US$1.0b
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
354
US$29.60
7D
5.7%
1Y
27.6%
Pharming Group
€491.5m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.70
7D
-0.7%
1Y
-34.1%